JP7849812B2 - パーキンソン病の検出方法 - Google Patents

パーキンソン病の検出方法

Info

Publication number
JP7849812B2
JP7849812B2 JP2021082827A JP2021082827A JP7849812B2 JP 7849812 B2 JP7849812 B2 JP 7849812B2 JP 2021082827 A JP2021082827 A JP 2021082827A JP 2021082827 A JP2021082827 A JP 2021082827A JP 7849812 B2 JP7849812 B2 JP 7849812B2
Authority
JP
Japan
Prior art keywords
disease
parkinson
genes
gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021082827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021180654A (ja
JP2021180654A5 (https=
Inventor
裕也 上原
高良 井上
信孝 服部
臣二 斉木
真一 上野
遙香 竹重
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Juntendo University
Original Assignee
Kao Corp
Juntendo University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp, Juntendo University filed Critical Kao Corp
Publication of JP2021180654A publication Critical patent/JP2021180654A/ja
Publication of JP2021180654A5 publication Critical patent/JP2021180654A5/ja
Application granted granted Critical
Publication of JP7849812B2 publication Critical patent/JP7849812B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021082827A 2020-05-14 2021-05-14 パーキンソン病の検出方法 Active JP7849812B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020085430 2020-05-14
JP2020085430 2020-05-14

Publications (3)

Publication Number Publication Date
JP2021180654A JP2021180654A (ja) 2021-11-25
JP2021180654A5 JP2021180654A5 (https=) 2025-04-21
JP7849812B2 true JP7849812B2 (ja) 2026-04-22

Family

ID=78525192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021082827A Active JP7849812B2 (ja) 2020-05-14 2021-05-14 パーキンソン病の検出方法

Country Status (5)

Country Link
US (1) US20230183806A1 (https=)
EP (1) EP4151752A4 (https=)
JP (1) JP7849812B2 (https=)
CN (1) CN115605608A (https=)
WO (1) WO2021230379A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4180536A4 (en) * 2020-07-10 2024-08-07 Kao Corporation Method for detecting severity of atopic dermatitis
KR20240143936A (ko) * 2023-03-21 2024-10-02 주식회사 키베이직 콧물 시료를 이용한 반려동물의 인지 장애 진단용 조성물
CN117051102B (zh) * 2023-10-12 2024-01-26 上海爱谱蒂康生物科技有限公司 生物标志物组合在制备预测帕金森病的产品中的应用
CN119685467A (zh) * 2023-12-01 2025-03-25 上海市东方医院（同济大学附属东方医院） 诊断和治疗阿尔茨海默病的医药制剂
JP2025170775A (ja) * 2024-05-07 2025-11-19 花王株式会社 情報処理装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018008319A1 (ja) 2016-07-08 2018-01-11 花王株式会社 核酸試料の調製方法
WO2020025967A1 (en) 2018-08-01 2020-02-06 The University Of Manchester Biomarkers and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100644364B1 (ko) * 2005-03-04 2006-11-10 한국생명공학연구원 파킨슨병 유전자 마커 및 이를 이용한 파킨슨병 진단킷트
JP6565010B2 (ja) 2014-10-09 2019-08-28 有限会社ピコデバイス パーキンソン病の早期診断方法
WO2017136662A1 (en) 2016-02-05 2017-08-10 St. Johns University Circulating serum microrna biomarkers and methods for determining parkinson's disease
CN109337975A (zh) * 2018-12-24 2019-02-15 潘伟 基因标志物在帕金森诊断中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018008319A1 (ja) 2016-07-08 2018-01-11 花王株式会社 核酸試料の調製方法
WO2020025967A1 (en) 2018-08-01 2020-02-06 The University Of Manchester Biomarkers and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Noncoding RNA Investigation，2017年，doi:10.21037/ncri.2017.12.02
統計数理，2006，第 54 巻, 第 2 号，p.405-423
臨床神経学，2012年，Vol.52, No.11，p.1332-1334

Also Published As

Publication number Publication date
US20230183806A1 (en) 2023-06-15
EP4151752A4 (en) 2025-08-13
EP4151752A1 (en) 2023-03-22
JP2021180654A (ja) 2021-11-25
CN115605608A (zh) 2023-01-13
WO2021230379A1 (ja) 2021-11-18

Similar Documents

Publication Publication Date Title
JP7849812B2 (ja) パーキンソン病の検出方法
JP7743217B2 (ja) アトピー性皮膚炎の重症度の検出方法
JP7762549B2 (ja) アトピー性皮膚炎の症度変化の検出方法
JP7743475B2 (ja) アトピー性皮膚炎の検出方法
JP2022049694A (ja) 乳幼児アトピー性皮膚炎の検出方法
JP7743289B2 (ja) アトピー性皮膚炎の症度の検出方法
JP7845827B2 (ja) 月経前症候群の重症度検出方法
JP2022164646A (ja) 乳幼児おむつ皮膚炎の症度の検出方法
JP7847451B2 (ja) アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法
JP7847450B2 (ja) アトピー性皮膚炎の症度悪化の検出方法
JP2023002298A (ja) 糖尿病指標値の検出方法
JP7767500B2 (ja) アトピー性皮膚炎の重症度の検出方法
JP7750481B2 (ja) 内臓脂肪面積の検出方法
JP7743474B2 (ja) 乳幼児アトピー性皮膚炎の検出方法
JP2023073135A (ja) 更年期障害の重症度の検出方法
JP2023073134A (ja) ホットフラッシュの検出方法
JP2023048811A (ja) 疲労の検出方法
JP2022164647A (ja) 乳幼児顔湿疹の症度の検出方法
JP2023048810A (ja) 慢性ストレスレベルの検出方法
JP2024075099A (ja) アンモニア代謝能力の検出方法
JP2023045067A (ja) 不眠の検出方法
JP2024045047A (ja) 肥満改善剤の有効性予測方法
JP2023069499A (ja) 乾燥による皮膚表面形状悪化の検出方法
JP2024045048A (ja) 肥満改善剤の有効性予測方法
JP5861048B1 (ja) 遺伝子発現解析による大腸癌の検出

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260331

R150 Certificate of patent or registration of utility model

Ref document number: 7849812

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150